ITCI vs. TAK, ARGX, BNTX, TEVA, BGNE, GMAB, VTRS, SMMT, MRNA, and RDY
Should you be buying Intra-Cellular Therapies stock or one of its competitors? The main competitors of Intra-Cellular Therapies include Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Genmab A/S (GMAB), Viatris (VTRS), Summit Therapeutics (SMMT), Moderna (MRNA), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.
Intra-Cellular Therapies vs.
Intra-Cellular Therapies (NASDAQ:ITCI) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, community ranking, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.
Intra-Cellular Therapies currently has a consensus price target of $100.31, suggesting a potential downside of 20.88%. Given Intra-Cellular Therapies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Intra-Cellular Therapies is more favorable than Takeda Pharmaceutical.
In the previous week, Intra-Cellular Therapies had 21 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 23 mentions for Intra-Cellular Therapies and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.74 beat Intra-Cellular Therapies' score of 0.31 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.
Takeda Pharmaceutical has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Takeda Pharmaceutical has a net margin of 6.49% compared to Intra-Cellular Therapies' net margin of -14.07%. Takeda Pharmaceutical's return on equity of 10.00% beat Intra-Cellular Therapies' return on equity.
92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Intra-Cellular Therapies has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.
Intra-Cellular Therapies received 422 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 67.53% of users gave Intra-Cellular Therapies an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
Summary
Intra-Cellular Therapies beats Takeda Pharmaceutical on 11 of the 19 factors compared between the two stocks.
Get Intra-Cellular Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intra-Cellular Therapies Competitors List
Related Companies and Tools
This page (NASDAQ:ITCI) was last updated on 1/21/2025 by MarketBeat.com Staff
